Great Robotics Secures Tens of Millions in Angel Funding Led by Inno Angel Fund to Advance Precision Imaging-Guided Surgical Robots

VCBeat has learned that Great Robotics, a developer of precision imaging surgical robots, has completed an angel financing round worth tens of millions of yuan. The round was solely led by Inno Angel Fund. The proceeds will be used to expand and develop the core technologies of the company’s surgical robot platform, which will then be translated into multiple product solutions.

Geerui Technology is an innovative medical robotics company that leverages its core technology platform of “precision image-guided” surgical robots to address clinical needs and pain points. It develops a series of surgical robots, providing customers with integrated solutions encompassing “precision imaging + intelligent software + surgical robots + dedicated consumables,” and promotes these offerings through innovative marketing models.

Surgical robots represent the next generation of surgical procedures. Leveraging technological advancements, they enable a shorter learning curve for surgeons, more standardized outcomes, and greater efficiency, while also minimizing patient trauma and shortening postoperative recovery time.

From a policy perspective, China has intensified support for domestically produced devices. Coupled with abundant clinical research resources and the rapid development of AI applications, the market share of domestic robots is increasing year by year. They are expected to dominate the market in the future, with a clear trend toward import substitution driven by policy support and technological advancements. In terms of market conditions, China boasts a large and rapidly growing surgical robot market. This growth is fueled by an aging population within its vast demographic base and rising healthcare demands due to improved living standards. Given the currently low penetration rate, there is significant potential for future market expansion.

From the perspective of specific application scenarios, the high incidence rates of orthopedic, neurological, and vascular diseases both domestically and internationally have resulted in a large patient population. Many pain points associated with traditional surgeries urgently need to be addressed, making precision treatment—particularly surgical robot-assisted procedures under “precision image guidance”—the future direction of development. In terms of market maturity, the domestic market has moved beyond the early stage of market education, and the clinical community has fully recognized the value of surgical robots. Currently, what departments and hospitals lack are efficient, stable, and cost-effective solutions to facilitate widespread adoption.

Leveraging its robust technological reserves and specialized clinical expertise in niche fields, GuiRui Technology was established to focus on system-level solutions for “precision image-guided” surgical robots. Adopting a large-platform development strategy, its product portfolio will gradually expand from orthopedics and neurosurgery to interventional and general surgery. GuiRui Technology aims to become a leading enterprise of scale in the field of surgical robotics.

“GeRui” is a transliteration of the English word “Great,” which embodies the team’s long-term vision: to pursue continuous innovation and become a great surgical robotics company. Delving deeper, the Chinese name “GeRui” conveys the spirit of “advancing boldly with high morale and pioneering innovation,” reflecting the team’s passion for innovation. Guided by its mission, “Endless Exploration for Human Health,” GeRui Technology is committed to achieving its overarching goal of making surgery more precise, safe, and efficient, while enhancing the cost-effectiveness of surgical robots.

The founder of Gerui Technology graduated from Tsinghua University and possesses a comprehensive research background in mechatronics, robotics, and 3D printing. He has successively held senior management positions, such as Chief Expert and Vice President, at leading multinational medical corporations and domestic medical device companies. Notably, the founder serves as the Chief Engineer for a key national R&D program under the Ministry of Science and Technology and is a seasoned expert in the field with extensive experience in the medical device industry.

The founding core team of Geer Technology hails from prestigious institutions including Tsinghua University, Beihang University, the Chinese Academy of Sciences, Tianjin University, as well as renowned universities in the United States, Canada, and Israel. With over a decade of intrapreneurial experience at leading multinational and domestic medical enterprises, the team has successfully developed multiple Class III medical products in the fields of orthopedics and minimally invasive interventional procedures, along with dozens of innovative technological achievements. The cumulative output value of their China-made medical products has exceeded RMB 10 billion to date, demonstrating robust innovation and scalability capabilities. Furthermore, the team possesses excellent global and local perspectives alongside practical experience, positioning it as a vital force in propelling high-end Chinese medical devices onto the world stage.

In terms of its development model, Ge Rui Technology adopts a “1+N+M” platform-based development strategy, whereby a single technology platform rapidly gives rise to N solutions and products that address M application scenarios, thereby efficiently achieving a modular product portfolio and establishing competitive barriers. Currently, Ge Rui Technology is sequentially launching a variety of surgical robot products, providing systematic solutions that integrate precision imaging, intelligent software, assistive surgical robots, and instrumental consumables.

In terms of its business model, Geerui Technology will abandon the traditional approach centered solely on equipment or consumables, and instead forge a new model that integrates standardized products, consumables, and services with customized offerings. This strategy expands the scope of clinical applications and provides customers with more open functionalities and interfaces, enabling them to fully participate in clinical and product innovation.

It is understood that GeRui Technology’s projects are currently advancing rapidly, and the company is about to officially commence its Pre-A financing round to support the subsequent rapid growth of its team and business.

Zhou Quan, Partner at Inno Angel Fund, stated that medical robots can achieve more precise, safer, and more stable surgical outcomes. The Equivir team possesses extensive experience in the successful development and commercialization of Class III medical devices. By integrating precise imaging, navigation, and surgical assistance into a systematic solution, they have expanded the clinical scope of application, met rigid clinical demands, and enhanced system intelligence and operational simplicity. Inno Angel Fund is optimistic about the team’s ability to provide comprehensive clinical solutions based on surgical robots, thereby better empowering clinicians and delivering higher-quality medical services to patients.

Inno Angel Fund was established in April 2013. Its investment management team has an average of over 10 years of experience, and the fund manages assets exceeding RMB 4 billion. Guided by its mission of “Investing in Innovation, Achieving Mutual Success,” Inno Angel Fund focuses on angel and Pre-A round investments in advanced manufacturing (chips, robotics, aerospace, etc.), next-generation information technology, life sciences, new energy, new materials, and mass consumption & new cultural creativity. Since its inception, the firm has consistently been honored with accolades such as “Top 10 Early-Stage Investment Institutions in China.”